Content Type: Article

  • IRS Waging New Audit Campaigns Against Business Taxpayers

    ARTICLE

    IRS Waging New Audit Campaigns Against Business Taxpayers

    July 7, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Robin Greenhouse, Chelsea Hess and Kevin Spencer wrote this bylined article on IRS plans to audit corporate taxpayers using “campaigns” focused on one tax issue. “We expect the IRS to implement numerous additional campaigns as the program kicks into high gear, and it is possible that a single taxpayer could come under scrutiny in more than one campaign,” the authors wrote, adding that they expect “a heavy focus on anything dealing with taxation of international transactions.”

    Read the full article.

    In depth
    Authors
    More insights

  • Managing the Transition to Transformation: The Strategic Implications of MACRA

    Managing the Transition to Transformation: The Strategic Implications of MACRA

    ARTICLE

    Managing the Transition to Transformation: The Strategic Implications of MACRA

    July 6, 2016

    Read time: 14 min

    Key takeaways
    Overview

    McDermott’s Managing the Transition to Transformation series is designed to help health systems and other health care industry leaders address the many challenges presented by the transformation in payment and care delivery models. The goal of this series is to help organizations prepare so that they are not only competitive, but can also thrive under alternative payment models (APMs) and quality-based reimbursement models (QBRs). This article discusses the strategic implications of MACRA and how your organization can build a winning strategy for success.

    In depth

    On April 27, the Centers for Medicare and Medicaid Services (CMS) unveiled the much-anticipated (and, for some, feared) proposal to implement the physician payment reforms required under the Medicare Access to Care and CHIP Reauthorization Act of 2015 (MACRA). These reforms, once implemented, will profoundly change how and how much Medicare pays physicians for services furnished to program beneficiaries by substantially linking such payments to performance and incentivizing physicians to participate in alternative payment models. Moreover, while not expressly intended by Congress or CMS, these changes also are likely to cause a dramatic increase in physician-physician consolidation and physician-hospital consolidation and alignment.

    Under the Merit-Based Incentive Payment System (MIPS) established in MACRA, and now described in detail by CMS in draft regulations, Medicare payments to physicians will be adjusted based on each physician’s performance in four performance categories: Quality, Resource Utilization, Clinical Practice Improvement Activities and Advancing Care Information. Medicare payments can be increased or decreased by as much as 9 percent once the program is fully implemented. If certain requirements are met, physicians can participate in an alternative payment model (APM), instead of MIPS, and receive a 5 percent payment bonus for doing so. Initially, status as an APM will be determined by reference to Medicare payments only. However, after a transition period, an entity can qualify for APM status based either on its Medicare participation or on its Medicare participation and its contracting in the commercial market.

    While Medicare payments to physicians will not be affected until 2019, the performance and reporting obligations that will determine payments in 2019 begin next year—on January 1, 2017. Consequently, health systems and independent physicians nationwide are racing to understand the new MACRA requirements, to estimate as best they can their likely effects, and to identify pathways to success in this new regime. By CMS’s own analysis, 78 percent of physicians in groups of less than 10 practitioners subject to MIPS (because they cannot or choose not to participate in an APM) are likely to see their Medicare payments negatively adjusted upon implementation of the new payment scheme (see, Table 64, Medicare Program; Merit-Based Incentive Payment System and Alternative Payment Model Incentive Under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models; Proposed Rule, 81 Fed. Reg. 28,162, 28,375 [May 9, 2016]). CMS’s estimate most likely is based on the expectation that physicians who do not figure out success strategies will subject themselves to a downward reimbursement spiral where Medicare payments deteriorate because of poor performance, and deteriorating payments beget further poor performance.

    While MACRA grabbed headlines as a “fix” to the sustainable growth rate formula for Medicare payments to physicians, and the annually compounding problem it had become, MACRA will also create powerful incentives that will accelerate the reshaping of the physician services market. It will encourage physicians to consolidate into larger groups, enter into arrangements with physician specialty management companies, or, most likely, become employed by or otherwise contractually aligned with health systems. Some physicians may choose to reduce their Medicare volumes (to take advantage of a low-volume exception) or opt out of Medicare altogether. Physician organizations will need to be of a certain size to permit access to increasingly expensive information technology and other care management infrastructure, which are necessary to support the data reporting and other incremental costs associated with MIPS. However, thriving, not just surviving, under MIPS will require substantial investments in information technology and other care management infrastructure that will be beyond the capacity of all but the largest physician organizations. Avoiding MIPS altogether and seizing the opportunities presented by APMs will require even greater size, scale and resources.

    Hospitals and health systems, physician specialty management companies and large, sophisticated multi-specialty group practices that make the investments now that will be needed to thrive under MACRA will be able to take advantage of the market disruption that MACRA will create, especially in the sole practitioner and small group practice portion of the physician services market. In particular, MACRA presents a once-in-a-generation strategic opportunity for physician growth and alignment for those systems, management companies and large group practices that can create physician employment and/or alignment models that: (1) offer relief from the direct burdens of MIPS compliance; (2) offer the opportunity for enhanced payments under MIPS; and/or (3) offer an APM as a superior alternative to MIPS. The further challenge will be doing this in a manner that is realistic and practical, but still sensitive to the concerns of physicians who are being driven to reluctantly give up traditional private practice.

    In our view, a winning strategy for success under MACRA, and payment transformation from fee-for-service (FFS) payments to value-based payments or APMs generally, should include offering a range of options under which physicians and physician groups can effectively and efficiently align with your organization. Such options might include:

    • Direct employment;
    • Leased or contracted employment under a “foundation” model that enables a physician to act as a day-to-day employee of the system, but is based on a contractual, not employment, relationship and allows physicians to remain in control of individual physician compensation;
    • The opportunity to join as an employee, leased employee or independent practice an APM entity sponsored by the system (in many cases, this would be a Next Generation Accountable Care Organization or a Track 2 or Track 3 Medicare Shared Savings Program ACO, though there are other options);
    • The opportunity to join as an independent practice a clinically-integrated network (CIN) that contracts in the commercial payor market and takes responsibility for many of the burdens associated with independent practice (e.g., MIPS compliance); or
    • The opportunity to buy services from a system-sponsored management services organization (MSO) that provides practice management support to independent practices.

    In addition to creating these options, systems will need to educate the physicians in their market about the transformative impacts of MACRA. This is not an entirely new value proposition. Physicians have been leaving small group practices for larger group practices and system employment for years for many similar reasons (e.g., better and/or more secure salary and benefits, relief from the administrative and regulatory burdens of independent practice, better clinical support, etc.). MACRA will dramatically and quickly accelerate this trend.

    While our thesis is that MACRA presents an opportunity to sophisticated and forward-looking players in the market, there is no doubt that MACRA presents many challenges as well, especially to hospital systems. The most notable of these challenges is that as “value” becomes the basis for physician services reimbursement, the success of the physician enterprise will increasingly be at odds with the success of the hospital enterprise, because “value,” in the form of cost-effectiveness, will be delivered by keeping patients healthy and out of the hospital. This is not a new problem for hospitals in commercial markets already in the midst of the transition from FFS payments to value-based models and other APMs, but it will intensify their problems. For hospitals still in primarily FFS markets, MACRA will present a new and significant challenge. As Medicare and commercial payers shift to value-based and other alternative payment models, systems will need to redesign their operations and reduce costs accordingly. While that work must happen, systems should not lose sight of the fact that MACRA presents a significant opportunity to create greater alignment with physicians, and a risk of losing this opportunity to their competitors. The brave new world of MACRA will create further impetus for the creation of hospital and physician systems that are fully integrated—clinically, operationally and financially.

    Authors

    Charles R. Buck

    Partner

    Boston

    Eric Zimmerman

    Partner

    Washington, DC

    More insights

  • NYDFS Issues AML/Sanctions Programs and Annual Certification Requirements for Banks, Money Transmitters and Check Cashers

    NYDFS Issues AML/Sanctions Programs and Annual Certification Requirements for Banks, Money Transmitters and Check Cashers

    ARTICLE / CLIENT ALERT

    NYDFS Issues AML/Sanctions Programs and Annual Certification Requirements for Banks, Money Transmitters and Check Cashers

    July 6, 2016

    Read time: 11 min

    Key takeaways
    Overview

    On June 30, 2016, the New York State Department of Financial Services (“NYDFS”) adopted a final regulation imposing new anti-money laundering (“AML”) and economic sanctions requirements on financial institutions regulated by the NYDFS (the “Final Rule”). The Final Rule requires all depository institutions, trust companies, foreign bank branches or agencies, money transmitters and check cashers chartered or licensed under New York law (each, a “Regulated Institution”) to maintain a “Transaction Monitoring Program” and a “Filtering Program” (collectively, a “Transaction Monitoring and Filtering Program”) to detect potential violations of applicable AML laws and regulations and sanctions programs administered by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”).[1]

    During the last few years, the NYDFS has conducted investigations on Bank Secrecy Act “BSA”/AML and sanctions compliance at financial institutions and reports that it has discovered shortcomings, particularly with respect to transaction monitoring and filtering systems, and governance, oversight and accountability at senior levels of such financial institutions. The Final Rule requires Regulated Institutions to review their Transaction Monitoring and Filtering Program and ensure that such program is reasonably designed to comply with risk-based safeguards. The Final Rule also requires Regulated Institutions to adopt an annual board resolution (“Resolution”) or senior officer compliance finding (“Finding”) to certify compliance with the Final Rule, which would potentially expose any such signatories to a regulatory penalty or criminal liability if the controls are found lacking. The Final Rule is effective Jan. 1, 2017, and Regulated Institutions will be required to prepare and submit to the NYDFS their annual Resolution or Finding commencing April 15, 2018.[2]

    The Final Rule would not apply to federally-chartered depository institutions or other financial institutions not chartered or licensed by the NYDFS. It also would not cover NYDFS-regulated insurance companies or persons subject to NYDFS’ digital currency regulations, which have separate NYDFS-imposed AML requirements and, in some cases, federal AML requirements.

    Key Requirements of the Final Rule and Differences Between the Proposed and Final Rule [3]

    While the Final Rule largely mirrors the proposed rule, there are a few significant differences. Most notably, the Final Rule is now risk-based, which is evidenced by several moderating phrases throughout the rule text, such as “reasonably designed,” “risk-based intervals,” “as relevant,” “to the extent they are applicable” and “as appropriate,” and Regulated Institutions now have the option of either submitting a Resolution from its board or a Finding from a senior officer. The key requirements of the Final Rule include the following:

    AML Transaction Monitoring Program

    Each Regulated Institution is required to maintain a program reasonably designed for the purpose of monitoring transactions after their execution for potential BSA/AML violations and Suspicious Activity Reporting. The system, which may be manual or automated, shall, at a minimum, include the following attributes, to the extent they are applicable:

    • Be based on the risk assessment of the Regulated Institution;
    • Be reviewed and periodically updated at risk-based intervals to take into account and reflect changes to applicable BSA/AML laws, regulations and regulatory warnings, as well as any other information determined by the Regulated Institution to be relevant from the Regulated Institution’s related programs and initiatives;
    • Appropriately match BSA/AML risks to the Regulated Institution’s businesses, products, services and customers or counterparties;
    • BSA/AML detection scenarios with threshold values and amounts designed to detect potential money laundering or other suspicious or illegal activities;
    • End-to-end, pre- and post-implementation testing of the Transaction Monitoring Program, including, as relevant, a review of governance, data mapping, transaction coding, detection scenario logic, model validation, data input and program output;
    • Documentation that articulates the Regulated Institution’s current detection scenarios and the underlying assumptions, parameters and thresholds;
    • Protocols setting forth how alerts generated by the Transaction Monitoring Program will be investigated, the process for deciding which alerts will result in a filing or other action, the operating areas and individuals responsible for making such a decision, and how the investigative and decision-making process will be documented; and
    • Be subject to an on-going analysis to assess the continued relevance of the detection scenarios, the underlying rules, threshold values, parameters and assumptions.

    OFAC Filtering Program

    Each Regulated Institution is required to maintain a filtering program reasonably designed for the purpose of interdicting transactions that are prohibited by OFAC sanctions, and which shall include the following attributes, to the extent they are applicable:

    • Be based on the risk assessment of the Regulated Institution;
    • Be based on technology, processes or tools for matching names and accounts, in each case based on the Regulated Institution’s particular risks, transaction and product profiles;
    • End-to-end, pre- and post-implementation testing of the Filtering Program, including, as relevant, a review of data matching, an evaluation of whether the OFAC sanctions list and threshold settings map to the risks of the institution, the logic of matching technology or tools, model validation, and data input and program output;
    • Be subject to on-going analysis to assess the logic and performance of the technology or tools for matching names and accounts, as well as the OFAC sanctions list and the threshold settings to see if they continue to map to the risks of the Regulated Institution; and
    • Documentation that articulates the intent and design of the Filtering Program tools, processes or technology.

    The proposed rule would have extended these requirements to unidentified “other sanctions lists, politically exposed persons lists, and internal watch lists.” That language has been dropped from the Final Rule, which is limited to OFAC prohibitions.

    Additional Requirements Applicable to the Transaction Monitoring and Filtering Program

    Both the Transaction Monitoring Program and the Filtering Program must require the following, to the extent they are applicable:

    • Identification of all data sources that contain relevant data;
    • Validation of the integrity, accuracy and quality of data to ensure that accurate and complete data flows through the Transaction Monitoring and Filtering Program;
    • Data extraction and loading processes to ensure a complete and accurate transfer of data from its source to automated monitoring and filtering systems, if automated systems are used;
    • Governance and management oversight, including policies and procedures governing changes to the Transaction Monitoring and Filtering Program to ensure that changes are defined, managed, controlled, reported and audited;
    • Vendor selection process if a third-party vendor is used to acquire, install, implement or test the Transaction Monitoring and Filtering Program or any aspect of it;
    • Funding to design, implement and maintain a Transaction Monitoring and Filtering Program that complies with the requirements of the regulation;
    • Qualified personnel or outside consultant responsible for the design, planning, implementation, operation, testing, validation and on-going analysis of the Transaction Monitoring and Filtering Program, including automated systems if applicable, as well as case management, review and decision making with respect to generated alerts and potential filings; and
    • Periodic training with respect to the Transaction Monitoring and Filtering Program.

    The proposed rule prohibited Regulated Institutions from making changes to their Transaction Monitoring and Filtering Program to avoid or minimize filing suspicious activity reports, or due to a lack of resources to review alerts generated by the program. This prohibition was omitted from the Final Rule. Instead, the Final Rule requires Regulated Institutions to “document the identification and remedial efforts planned and underway” to address any areas, systems or processes that the Regulated Institution believes require material improvement, updating or redesign.

    Annual Board Resolution or Senior Officer Compliance Finding

    The Final Rule requires each Regulated Institution to adopt and submit to the NYDFS a Resolution or Finding by April 15 of each year. A Regulated Institution can determine whether to submit a Resolution or Finding, “as appropriate,” although the Final Rule does not provide further guidance on when to submit a Resolution versus a Finding. A senior officer for this purpose does not need to be a compliance professional. The term “senior officer” is defined as “the senior individual or individuals responsible for the management, operations, compliance and/or risk of a Regulated Institution,”[4] and more than one senior officer can submit the required compliance finding. The Final Rule notes that the Board of Directors includes “the governing board of every Regulated Institution,” as well as “the functional equivalent if the Regulated Institution does not have a Board of Directors.”

    The Final Rule has an attachment that prescribes the wording of the Resolution or Finding. The Resolution or Finding requires the board or senior officer to certify that it, or he or she, has “reviewed documents, reports, certifications and opinions of such officers, employees, representatives, outside vendors and other individuals or entities as necessary,”[5] suggesting that the signatory may rely on reports or certifications of compliance by subordinates, similar to the process employed by public companies in certifying compliance with the requirements of the Sarbanes-Oxley Act. Nonetheless, the board or senior officer still must certify, to the best of the board’s or officer’s knowledge, that the Transaction Monitoring and Filtering Program complies with the Final Rule. The board or senior officer must also certify that it, or he or she, has “taken all steps necessary” to “confirm” that the Transaction Monitoring and Filtering Program complies with the Final Rule.[6] The requirement to “take[] all steps necessary” to confirm compliance was not part of the proposed rule, and the Final Rule offers no guidance as to what steps NYDFS expects signatories should take to satisfy this requirement.

    Although the language imposing criminal penalties for incorrect or false certifications on the Senior Compliance Officer has been removed in the Final Rule, the enforcement provision (§ 504.5) now states that the Final Rule will be enforced pursuant to the NYDFS’ authority under “any applicable laws,” and notes that the Final Rule is “not intended to limit, the Superintendent’s authority” under those laws. Such laws still include Section 672 of the New York Banking Law, which makes it a felony for any officer, director, trustee, employee or agent of a corporation subject to the New York Banking Laws — which could include both a Senior Compliance Officer or members of the Board of Directors — to make a false entry or material omission in any book, report or statement with intent to deceive a corporate officer or state regulator.[7]

    Each Regulated Institution must also maintain for examination by NYDFS all records, schedules and data supporting adoption of the Resolution or Finding for a period of five years. 

    Conclusion

    In order to meet the Jan. 1, 2017, effective date, Regulated Institutions should now begin assessing whether their AML and OFAC policies and procedures, and transaction monitoring systems, comply with the Final Rule, and develop procedures for documenting and tracking their compliance efforts. In addition, NYDFS-regulated banks and branches of foreign banks will also have to begin to implement during the same period FinCEN’s final rule on beneficial ownership and customer due diligence requirements, which is effective May 11, 2018.[8]

    Authored by Donald J. Mosher, Betty Santangelo, Gary Stein, Joseph P. Vitale, Seetha Ramachandran and Melissa G.R. Goldstein.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] A copy of the text of the Final Rule is available at www.dfs.ny.gov/legal/regulations/adoptions/dfsp504t.pdf. A copy of the press release is available at www.dfs.ny.gov/about/press/pr1606301.htm. 

    [2] The Final Rule will be set forth in Part 504 of the NYDFS Superintendent’s Regulations.

    [3] A copy of the proposed rule, which was issued Dec. 1, 2015, is available at www.dfs.ny.gov/legal/regulations/proposed/rp504t.pdf. Read the SRZ Client Alert, “NYDFS Proposes New AML/Sanctions Programs and Annual Certification Requirements for Banks, Money Transmitters and Check Cashers,” for a summary of the proposed rule.

    [4] Final Rule § 504.2(g).

    [5] Final Rule, Attachment A.

    [6] Final Rule, Attachment A.

    [7] N.Y. Bank. Law § 672.

    [8] Final Rule, Customer Due Diligence Requirements for Financial Institutions, 81 Fed. Reg. 29398 (May 11, 2016), available at www.gpo.gov/fdsys/pkg/FR-2016-05-11/pdf/2016-10567.pdf.


    This information has been prepared by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP (‘SRZ’) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    More insights

  • Insuring Against Yates: The Impact on D&O Insurance

    ARTICLE

    Insuring Against Yates: The Impact on D&O Insurance

    July 5, 2016

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Brexit: Will It Stop the European Unitary Patent Before It Starts?

    ARTICLE

    Brexit: Will It Stop the European Unitary Patent Before It Starts?

    July 4, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Boris Uphoff and Laura Morelli wrote this bylined article on the substantial impact that the Brexit vote will have on the new European Unitary Patent. “As a non-member of the EU, the UK will not be able to further participate in the Unitary Patent,” the authors wrote. ”Without the UK, with its market size and its reputation for patent litigation, the Unitary Patent will lose substantial value.”

    Read the full article.

    In depth
    Authors

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    More insights

  • BGH: No Early Repayment

    ARTICLE

    BGH: No Early Repayment

    June 2016

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Sebastian Keding wrote this bylined article detailing a decision by the BGH (The Federal Court of Justice [Bundesgerichtshof], Germany’s highest court of civil and criminal jurisdiction) regarding the applicability of early repayment clauses when non-performing loans have been created by the lender because it terminated the borrower prematurely due to late payments.

    In depth
    Authors
    More insights

  • Family Governance: Development of a Family Constitution

    Family Governance: Development of a Family Constitution

    ARTICLE

    Family Governance: Development of a Family Constitution

    July 2016

    Read time: 2 min

    Key takeaways
    Overview
    In depth

    Norbert Schulte wrote this bylined article on developing a family constitution to operate a family office. “The process of shared discussion and education creates family identification and rules of life,” Mr. Schulte wrote, adding that “for the family itself, it is important that the values of all members are taken into account to develop harmony in how the family office is run.”

    Authors
    More insights

  • Non-Compete Agreements: Friend or Foe?

    ARTICLE

    Non-Compete Agreements: Friend or Foe?

    Summer 2016

    Read time: 2 min

    Key takeaways
    Overview

    Marc Sorini and Anne Harris wrote this bylined article discussing how craft distillers can use non-compete or non-solicitation agreements with key employees. The authors cautioned that even where such agreements are appropriate “it isn’t quite as simple as having an employee sign the agreement. The agreement must be enforceable … [since] restrictive covenants are governed by different laws in different states and agreements that are poorly drafted are likely to be found unenforceable.”

    In depth
    Authors
    More insights

  • D&O Insurance—Issues to Consider Before a Claim Arises

    D&O Insurance—Issues to Consider Before a Claim Arises

    ARTICLE / CLIENT ALERT

    D&O Insurance—Issues to Consider Before a Claim Arises

    June 30, 2016

    Read time: 11 min

    Key takeaways
    Overview

    D&O liability insurance remains a vital issue for companies and their directors and officers. Specific policy provisions to focus on when renewing or purchasing D&O insurance are examined here.

    In depth

    Directors and officers (D&O) liability insurance remains a vital issue for companies and their directors and officers as potential sources of liability continue to evolve. More securities lawsuits were filed in the past year than in any year since 2008, reflecting increased liability risks surrounding mergers and acquisitions, and IPOs. And on September 9, 2015, the US Department of Justice (DOJ) issued the so-called “Yates Memo,” which reaffirmed the DOJ’s policy prioritizing enforcement against individuals allegedly involved in corporate crime. Beyond these headline-grabbing exposures, individual directors and officers at even relatively small companies and nonprofits remain subject to a variety of potential claims, from alleged fiduciary liability to shareholders, partners or donors, to claims by suppliers, customers or competitors.

    The best time to ensure that sufficient D&O insurance offered on the best available terms is in place is before a claim arises. In advising clients on D&O insurance for almost two decades, we have seen many coverage claims that might have been resolved more smoothly, and in some instances more successfully, if more favorable terms had been negotiated when purchasing the insurance.

    With the benefit of that experience, this paper identifies specific policy provisions to focus on when renewing or purchasing D&O insurance.

    Coverage Periods

    Insurers typically offer D&O insurance on a “claims-made” basis, which means a policy insures against liability arising from a claim first asserted against the insured during the policy period. D&O policies also require notice of a claim by a certain date, often the end of the policy period or thirty days thereafter. Taken together, the claims-made nature of D&O insurance and its notice requirements mean that for a claim to be covered by a policy, the claim must have been made and reported to the insurer during the policy period. This leads to several issues, all of which can and should be addressed when placing or extending D&O insurance.

    First, while there may be business- or insurance-related reasons to switch insurers at renewal, insurer continuity carries significant benefits. If a claim arises, reasonable minds may differ on when it was first asserted, or whether the policyholder’s prior “notice of circumstances that could give rise to a claim” was sufficient for the claim to relate back to when that notice was given. Such differences may result in successive insurers each denying coverage, with the policyholder caught in the middle. Renewing the policy with the same insurer each year moots most such disputes.

    Second, D&O insurance policies usually restrict coverage to claims arising out “wrongful acts” allegedly committed on or after the “retroactive date.” The retroactive date is typically the date on which the policyholder’s first D&O insurance policy with the insurer incepted. Accordingly, insurer continuity increases the time between that initial purchase and the current policy period, potentially also enlarging the scope of claims a renewed policy may cover.

    Finally, many insurers offer extended reporting periods. If the D&O insurance is not be renewed following the policy period, then the extended reporting period provides a limited amount of “tail” coverage for claims alleging wrongful acts prior to expiration of the initial policy period. A typical D&O policy offers a one-year extended reporting period, but insurers can provide longer ones (for a price). A pre-negotiated option to purchase an extended reporting period of up to six years provides the directors and officers with the valuable protection in the event of a corporate sale or insolvency.

    Who Is Covered

    Another threshold requirement is confirming that the policy insures the intended corporate entities and individuals.

    A policy typically covers an identified company and its subsidiaries, defined as any entity in which the insured organization has a 50 percent ownership interest, or the right to appoint the subsidiary’s board or management. Sometimes the insurance purchaser also wants to insure related companies that do not meet the subsidiary definition. One example could be a closely held company that has some common ownership with the insured company, but the insured company does not own the related company or have clearly defined rights of control. In this instance, one should seek a policy endorsement adding the related company as an insured, or explore a separate policy for the related company.

    Individual insureds typically include “any past, present or future duly elected or appointed director or officer, or the holder of an equivalent position,” as long as any potential claim alleges wrongful acts committed while acting in their capacity as such. Companies wishing to insure other management-level individuals who are entitled to corporate indemnification, but do not fall neatly within this definition (e.g., a “chairman emeritus,” members of an advisory committee to the board and/or management, in-house general counsel or an in-house risk manager) should state clearly to the insurer the intent to insure these individuals, and if necessary, obtain an endorsement identifying these positions as insured persons.

    What Claims Are Covered

    Generally, D&O policies provide at least three types of coverage. Side A or Executive Liability Coverage reimburses individual insureds for losses that are not indemnified by the company. Side B or Corporate Reimbursement Coverage reimburses the company for its indemnification of directors and officers. Finally, Side C or Entity Coverage covers claims made directly against the company; private companies enjoy coverage broader than that of public companies, which typically is limited to securities claims.

    Beyond these basic coverage grants, policies can vary significantly in the scope of their coverage. For example, until recently, most policies defined a covered “claim” narrowly to include only written demands for monetary or non-monetary relief, formal criminal or civil proceedings or government investigations initiated by a formal investigative order or notice targeting a specific insured. This definition restricted coverage for “informal” investigations of individual directors and officers, initiated by such measures as subpoenas, search warrants or requests for interviews and documents. Most D&O insurers now will expand their “claim” definition to include these informal investigative actions, but such expansion often must be requested specifically.

    Another issue to address when a policy is purchased or renewed is “presumptive indemnification.” Many policies presume that the insured company will indemnify the individuals to the fullest extent allowed by law, but if the company fails to do so for any reason other than financial distress, the individuals bear the adverse consequences. In this scenario, the coverage afforded the individuals typically is subject to the much higher Side B retention, meaning the individuals could be required to pay tens of thousands of dollars of defense costs or other loss before the insurer will begin to indemnify. This risk can be eliminated by deleting the “presumptive indemnification” provision, or modifying it to state that if the company fails to indemnify the insurer will defend and indemnify the individuals under Side A (typically with no retention) and the insurer’s recourse shall be against the company, not the individuals.

    The “presumptive indemnification” issue also can be eliminated by purchasing a separate Side A-only policy to complement the Side A/B/C policy. Other potential benefits of a separate Side A policy should a claim arise include the broadest available definition of “claim,” elimination of most coverage exclusions (including the often troublesome “insured versus insured” exclusion), a separate insurance limit for the individuals that cannot be exhausted by the company’s defense costs and losses, and no entanglement in bankruptcy proceedings should the company undergo financial distress.

    Defense Costs

    D&O policies typically do not impose duties to defend insureds. Instead, the insured retains control of the defense, and the insurer is obligated to pay the reasonable costs (that are usually part of—not in addition to—the policy’s limit of liability). Several issues often arise in the claim context.

    First, policies typically require the insurer to consent to defense-cost expenditures and the policyholder’s selection of defense counsel. One way to avoid disputes in this area is to ask the insurer to preapprove by endorsement a panel of potential counsel. Such provisions do not obligate the policyholder to choose a firm on the panel, but they provide a significant benefit to the policyholder if it does so.

    Second, insurers often condition reimbursement of defense costs on adherence to the insurer’s billing guidelines, which may include a rate cap. Such guidelines may not reflect the markets in which the policyholder operates or litigates on a regular basis. Discuss this issue with the insurer before the policy is placed to determine how the insurer evaluates the reasonableness of defense costs. These discussions can lead to an endorsement setting forth the billing practices (e.g., rates, timekeeping practices, administrative tasks, etc.) that the parties agree are reasonable (or unreasonable).

    Third, D&O insurance policies historically indemnified defense costs on a “reimbursement” basis at the conclusion of the underlying claim, but in recent years most policy forms state expressly that the insurer shall “advance” costs while the claim is ongoing. This language can be improved further to require advancement within a specific time period after defense costs are incurred (e.g., 60 or 90 days). Obtaining this commitment is particularly important for the individual directors and officers under Side A, as payment of substantial defense costs from their personal assets while awaiting reimbursement from the insurer may not be a viable option.

    Conduct Exclusion

    Insurers issue D&O insurance subject to various exclusions, some of which are negotiable.

    A key exclusion bars coverage when the insured’s conduct was dishonest, criminal, fraudulent, or the insured obtained an improper profit. This exclusion comes in several variations; a more favorable one requires the finding of intentional conduct by a “final adjudication,” meaning an interlocutory finding or mere evidence of the conduct will not trigger the exclusion. Further, the exclusion may require that someone other than the insurer procure the finding, meaning that the insurer cannot try to obtain the necessary finding in a coverage dispute. Finally, the exclusion may state it is inapplicable to defense costs, which protects policyholders from having to repay defense costs even when a final adjudication bars coverage for indemnity. The policyholder-friendly variations should be requested if the insurer does not initially offer them.

    Potential Company Bankruptcy

    At no time is D&O insurance more important to covered individuals than when their company enters bankruptcy and cannot indemnify them. When the company is in financial distress, claims against the directors and officers become more likely, but the D&O insurance policy may be subject to the bankruptcy stay and the trustee’s efforts to marshal the company’s assets.

    This risk can be mitigated by obtaining several important protections when purchasing a policy. Some insurers offer a bankruptcy-protection provision, which states expressly that the policy is intended to benefit the individual directors and officers, and in the event of a bankruptcy, the insureds agree to waive any stay and not to oppose the efforts of the insurer or any insured to access the policy proceeds.

    Most policies contain an “order of payments” provision that requires the insurer to first pay non-indemnified defense costs and losses of the individual directors and officers, before paying the company’s claim for reimbursement of indemnity payments, or the costs of direct claims against the company. But some policies state expressly that the insured company’s bankruptcy does not relieve the insurer of its obligations to prioritize payments on behalf of the individual insureds.

    Finally, the advantages of a separate Side A policy in the bankruptcy context bear repeating: Because the policy does not insure the company, it is not an asset of the estate. Moreover, Side A policies typically contain the favorable language exempting the policy from a bankruptcy stay and memorializing the individual directors’ and officers’ right to the policy proceeds should the company enter bankruptcy or a similar proceeding.

    The Benefits of a Proactive Approach When Purchasing or Renewing D&O Insurance

    The best time to address these issues is at the time of policy placement or renewal with the assistance of an experienced insurance broker and insurance counsel. A proactive approach when purchasing the policy can avoid delay, expense and an unsatisfactory result if a claim arises.

    Authors

    Joshua David Rogaczewski

    Partner & Deputy General Counsel

    Washington, DC

    More insights

  • IP Update, Vol. 19, No. 6

    IP Update, Vol. 19, No. 6

    ARTICLE

    IP Update, Vol. 19, No. 6

    June 2016

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    More insights